Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer

Nuclear Medicine Review

Volumn 7, Issue 1, 2004, Pages 13-19

  Kovatcheva, Roussanka D ^a   Hadjieva, Tatjana D ^a   Kirilov, Georgi G ^a   Lozanov, Bojan S ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Differentiated thyroid cancer; Radioiodine therapy; Recombinant human TSH

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROTROPIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG UPTAKE; FEMALE; FOLLICULAR CARCINOMA; HUMAN; LUNG METASTASIS; LUNG NODULE; LYMPH NODE; MALE; METASTASIS; ONCOCYTOMA; RECURRENT CANCER; SIDE EFFECT; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME;

EID: 2942513008     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. De Groot LJ, Kaplan EL, McMormick M, Strauss FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-424.
2. Schlumberger M. Papillary and follicular thyroid carcinoma. New Engl J Med 1998; 338: 297-306.
3. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
4. 131I uptake post-thyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980; 50:734-739.
5. Schlumberger M, Charbord P, Fragu P et al. Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. J Clin Endocrinol Metab 1983; 57: 148-151.
6. Dow KH, Ferrell B, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7: 613-619.
7. Schlumberger M, Ricard M, Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol 2000; 143: 557-563.
8. Haugen BR, Pacini F, Reiners C et al. Comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-3885.
9. Ladenson PW, Braverman LE, Mazzaferri EL et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med, 1997; 337: 888-896.
10. Sziklas JJ, Mathews J, Spencer RP, Rosenberg RJ, Ergin MT, Bower BF. Thyroid carcinoma metastatic to pituitary [letter]. J Nucl Med 1995; 26: 1097.
11. 131I scanning with recombinant human thyrotropin vs. thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996; 81: 1724-1725.
12. Rotman-Pikielny P, Reynolds JC, Barker WC, Yen PM, Skarulis MC, Sarlis NJ. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 2000; 85: 237-244.
13. Luster M, Reinhardt W, Korber C et al. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest 2000; 23: 473-475.
14. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000; 10: 767-778.
15. Mazzaferri EL, Massoll N. Management of papillary and follicular differentiated thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002; 9: 227-247.
16. 131I. J Endocrinol Invest, 1999; 22 (Suppl): 17-24.
17. Meier CA, Braverman LE, Ebner SA et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78: 188-196.
18. Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002; 12: 583-590.
19. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87: 3242-3247.
20. Pacini F, Molinaro E, Lippi F et al. 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 5686-5690.
21. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87: 1490-1498.
22. Robbins RJ, Tuttle RM, Sharaf RN et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 619-625.
23. Robbins RJ, Tuttle RM, Sonenberg M et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001; 11: 865-869.
24. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002; 12: 37-43.
25. 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 2003; 148: 19-24.
26. Berg G, Lindstedt G, Suurküla M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002; 25: 44-52.
27. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 3640-3645.
28. Mariani G, Ferdeghini M, Augeri C et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharm 2000; 15: 211-217.
29. Lippi F, Capezzone M, Angelini F et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001; 144: 5-11.
30. 131I reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28: 1888-1889.
31. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-1492.
32. Biondi B, Palmieri EA, Pagano L et al. Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer. J Clin Endocrinol Metab 2003; 88: 211-214.
33. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract 2000; 6: 460-464.
34. Giovanni V, Arianna LG, Antonio C et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf. 2002) 2000; 56: 247-252.
35. Braga M, Ringel MD, Cooper DS, Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001; 86: 5148-5151.
36. Muller V, Bohuslavizki KH, Klutmann S, Clausen M. Value of recombinant human thyrotropin in high-dose radioiodine therapy: a case report. J Nucl Med Technol 2002; 30: 185-188.
37. Gruenwald F, Menzel C, Bender H. Dedifferentiation therapy induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39: 1903-1906.